Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -54.76% and +0.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +18.75% and +2.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
Ocugen (NASDAQ:OCGN) Trading 12.4% Higher - Time to Buy?
Ocugen (NASDAQ:OCGN) Trading Up 12.4% - What's Next...
MarketBeat·1mo ago
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritten offering of common stock.read more...
Benzinga·1mo ago
Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital
Chardan Capital reissued a "buy" rating and set a $7.00 price objective on shares of Ocugen in a report on Tuesday...
MarketBeat·1mo ago
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update
Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the target of a large decline in short interest in December. As of December 31st, there was short interest totaling 46,392,427 shares, a decline of...
MarketBeat·1mo ago
Ocugen Stock Is Surging Today: What's Driving The Action?
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.read more...
Benzinga·1mo ago
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage
Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, with no serious safety issues.read more...